Payment overview · 2025
General Payments
$954.54
45 reported records · 16 companies
Healthcare provider profile · identity verified
Mohammad Yunus, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BONIFAY, FL · NPI 1730165259
Verified facts
What the public records show
CMS Open Payments records show Mohammad Yunus, MD received $954.54 in general payments during 2025 across 45 reported records.
Verona Pharma, Inc. accounted for 16.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Qulipta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 288 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 288 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $153.95 | 16.1% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $140.76 | 14.8% | 8 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $97.05 | 10.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $91.60 | 9.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.37 | 7.3% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $68.34 | 7.2% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $68.11 | 7.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $66.87 | 7.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.09 | 5.5% | 3 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $41.33 | 4.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.64 | 2.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.13 | 2.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.34 | 1.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.52 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.83 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.61 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $954.54 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $153.95 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $102.18 | 6 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $71.15 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $68.34 | 3 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $68.11 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $66.87 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $55.50 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.22 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $44.22 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $41.33 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $38.58 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.10 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.25 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.25 | 2 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $25.90 | 1 | 2025 |
Source payment records
|
|||||
| HYMPAVZI Normalized: hympavzi |
Drug | PFIZER INC. | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
288 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
76 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
288 | 30 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 739 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 433 | 75 |
| Furosemide | Furosemide | 319 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 298 | 50 |
| Eliquis | Apixaban | 288 | 30 |
| Gabapentin | Gabapentin | 269 | 64 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 201 | 23 |
| Potassium Chloride | Potassium Chloride | 186 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 182 | 28 |
| Carvedilol | Carvedilol | 179 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 176 | 35 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 165 | 16 |
| Metformin Hcl | Metformin Hcl | 161 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 39 |
| Lisinopril | Lisinopril | 156 | 38 |
| Losartan Potassium | Losartan Potassium | 154 | 33 |
| Donepezil Hcl | Donepezil Hcl | 147 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 29 |
| Trazodone Hcl | Trazodone Hcl | 130 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 20 |
| Sertraline Hcl | Sertraline Hcl | 97 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 26 |
| Divalproex Sodium | Divalproex Sodium | 88 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 15 |
| Omeprazole | Omeprazole | 85 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 15 |
| Memantine Hcl | Memantine Hcl | 84 | 18 |
| Clonazepam | Clonazepam | 82 | 22 |
| Buspirone Hcl | Buspirone Hcl | 80 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 13 |
| Entresto | Sacubitril/Valsartan | 76 | 11 |
| Allopurinol | Allopurinol | 75 | 14 |
| Meloxicam | Meloxicam | 75 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 74 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 69 | 17 |
| Myrbetriq | Mirabegron | 67 | 11 |
| Spironolactone | Spironolactone | 66 | 14 |
| Levetiracetam | Levetiracetam | 64 | 13 |
| Mirtazapine | Mirtazapine | 64 | 23 |
| Trulicity | Dulaglutide | 60 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 14 |
| Lorazepam | Lorazepam | 51 | suppressed |
| Simvastatin | Simvastatin | 51 | 11 |
| Baclofen | Baclofen | 50 | suppressed |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Alprazolam | Alprazolam | 49 | 11 |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 32 |
| Latanoprost | Latanoprost | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 46 | suppressed |
| Finasteride | Finasteride | 45 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 13 |
| Methocarbamol | Methocarbamol | 43 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | suppressed |
| Cephalexin | Cephalexin | 41 | 25 |
| Morphine Sulfate | Morphine Sulfate | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Diazepam | Diazepam | 40 | suppressed |
| Glipizide | Glipizide | 40 | suppressed |
| Olanzapine | Olanzapine | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Pregabalin | Pregabalin | 36 | 12 |
| Prednisone | Prednisone | 35 | 16 |
| Sodium Chloride | 0.9 % Sodium Chloride | 35 | 16 |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 14 |
| Montelukast Sodium | Montelukast Sodium | 33 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Cilostazol | Cilostazol | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 28 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 16 |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 25 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | 11 |
| Primidone | Primidone | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Nystatin | Nystatin | 23 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 22 | suppressed |
| Clozapine | Clozapine | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Klor-Con 8 | Potassium Chloride | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | 12 |
| Glimepiride | Glimepiride | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Procrit | Epoetin Alfa | 17 | suppressed |
| Qulipta | Atogepant | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Lamivudine | Lamivudine | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 11 | suppressed |
| Prezista | Darunavir | 11 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $954.54 · 45 records | Verona Pharma, Inc. | AIRSUPRA, Arikayce, CAPLYTA, COBENFY, Cologuard Collection Kit, ENTYVIO, EVENITY, FANAPT, FARXIGA, GLASSIA, HYMPAVZI, LEQVIO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, Prolastin-C Liquid, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VRAYLAR, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error